Silexion Therapeutics (SLXNW)

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

Η τιμή μετοχής Silexion Therapeutics Corp Warrant (SLXNW) σήμερα είναι , δηλώνοντας μια κίνηση NaN% εφόσον η αγορά άνοιξε. Η κεφαλαιοποίηση αγοράς της εταιρείας είναι , με ημερήσιο όγκο συναλλαγών μετοχών . Η προηγούμενη τιμή κλεισίματος ήταν .

Έτοιμοι να ξεκινήσετε; Ακολουθήστε τα παρακάτω βήματα ή διαβάστε τον οδηγό μας για πώς να αγοράσετε Silexion Therapeutics μετοχή στο Kraken ξεκινώντας από 10 $.